Screener
Stoke Therapeutics, Inc. STOK Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 39,673 | 32,676 |
| Sales, general and administrative | 19,974 | 14,653 |
| Total operating expenses | 59,647 | 47,329 |
| (Loss) income from operations | (53,418) | 111,240 |
| Other income (expense): | ||
| Interest income (expense), net | 3,397 | 2,889 |
| Other income | 18 | 28 |
| Total other income (expense) | 3,415 | 2,917 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s operating income?
- Stoke Therapeutics, Inc. (STOK) reported operating income of -$53.42M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s operating income changed year-over-year?
- Stoke Therapeutics, Inc.'s operating income decreased by 148.0% year-over-year, from $111.24M to -$53.42M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s operating income has grown at a -30.1% compound annual growth rate (CAGR), from -$86.07M to -$20.59M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Stoke Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude